Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trials (PDQ®)

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Basic Trial Information
Trial Description
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IBiomarker/Laboratory analysis, TreatmentActive18 and overPharmaceutical / IndustryCA186-017

Trial Description


The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma

Further Study Information

Intervention model: Dose Escalation (part 1) of study= Sequential Design; Dose Expansion (part 2) of study= Parallel Design

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Clinical diagnosis of relapsed/refractory B-cell Malignancies (B-Non-Hodgkins Lymphoma (NHL)) per International Workshop Group (IWG)
  • Progressed or refractory to at least 1 prior line of standard therapy
  • Subjects in Expansion cohorts are restricted to relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or Follicular Lymphoma (FL) subjects who are either relapsed or refractory to prior rituximab or ritxumab-containing chemotherapy regimens
  • Follicular Lymphoma (FL) must have at least 1 lesion that can be biopsied at screening and on treatment
  • Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria:

  • Active or progressing brain metastases
  • Other concomitant malignancies (with some exceptions per protocol)
  • Active or history of autoimmune disease
  • Positive test for human immunodeficiency virus (HIV) 1&2 or known Acquired immune deficiency syndrome (AIDS)
  • History of any hepatitis (A, B or C)
  • History of grade 3-4 drug-related hepatitis
  • Known current drug or alcohol abuse
  • Active tuberculosis (TB)
  • Prior therapy with any antibody/drug that targets the T cell coregulatory proteins, including but not limited to, anti-CD137, Anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) or Anti-Glucocorticoid-induced tumor necrosis factor receptor (anti-GITR). However, Anti-Programmed Death-1 (anti-PD-1), Anti-Programmed Death-Ligand1 (anti-PD-L1) are permissible as prior therapy

Trial Contact Information

Trial Lead Organizations/Sponsors

Bristol-Myers Squibb Company - New York

Bristol-Myers SquibbStudy Director

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:

Trial Sites

  Los Angeles
 Jonsson Comprehensive Cancer Center at UCLA
 John Timmerman, Site 0011 Ph: 310-582-4060
 Stanford Cancer Center
 Ronald Levy, Site 0001 Ph: 650-725-6452
 University of Miami Sylvester Comprehensive Cancer Center - Miami
 Izidore Lossos, Site 0012 Ph: 305-243-4785
  Miami Beach
 Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
 Jose Lutzky, Site 0025 Ph: 305-535-3300
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 Brian Link, Site 0004 Ph: 319-353-8504
 Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
 Caron Jacobson, Site 0020 Ph: 617-632-5847
 Barbara Ann Karmanos Cancer Institute
 Radhakrishnan Ramchandren, Site 0023 Ph: 313-576-8722
New Jersey
 Hackensack University Medical Center Cancer Center
 Martin Gutierrez, Site 0015 Ph: 551-996-5499
New York
  New York
 Memorial Sloan-Kettering Cancer Center
 Andrew Zelenetz, Site 0010 Ph: 212-639-2656
North Carolina
 Levine Cancer Institute at Carolinas Medical Center
 Nilanjan Ghosh, Site 0022 Ph: 980-442-4363
 Providence Cancer Center at Providence Portland Medical Center
 John Godwin, Site 0002
 Hospital of the University of Pennsylvania
 Sunita Nasta, Site 0024 Ph: 215-662-6933
 M. D. Anderson Cancer Center at University of Texas
 Sattva Neelapu, Site 0018 Ph: 713-563-3429
 University of Virginia Cancer Center
 Craig Portell, Site 0009 Ph: 434-924-9637

Link to the current record.
NLM Identifer NCT01775631 processed this data on April 20, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top